Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A post hoc analysis of the NPC002 trial found that arimoclomol combined with miglustat significantly slowed disease progression in Niemann-Pick disease type C (NPC) patients — with benefits visible as early as 3 months in. The findings, presented at CNS 2026, are notable because NPC progression typically requires at least 12 months of observation to detect meaningful change.
First-ever NPC therapy shows benefits as early as 3 months in children and adults
New post hoc data from the phase 2/3 NPC002 trial, presented at the 55th Child Neurology Society Annual Meeting, reveal that arimoclomol (Miplyffa) plus miglustat significantly slowed disease progression in patients with Niemann-Pick disease type C (NPC) — and the treatment effect emerged as early as 3 months after starting therapy. That's a meaningful finding, since NPC progression typically requires at least 12 months of observation to detect differences between treatment groups.
The analysis focused on 39 patients who received concomitant miglustat, using the rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS), which tracks ambulation, speech, swallowing, and fine motor skills. Treatment differences consistently favored arimoclomol at every timepoint assessed — 3, 6, 9, and 12 months. Arimoclomol received FDA approval in September 2024 as the first-ever treatment for NPC's neurological symptoms in patients aged 2 and older.
By the Numbers
Why it matters: NPC is an ultra-rare, fatal neurodegenerative disease with no prior approved treatments. Evidence that arimoclomol's benefits appear within just 3 months could help clinicians and families gauge treatment response sooner — though the post hoc design and small subgroup size call for cautious interpretation.
